Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR Newswire•20/10/2026•17:23 ET
1
Key Highlights
- ➤Atrium Therapeutics (RNA) granted options for 9,500 shares at $7.98 exercise price
- ➤Atrium Therapeutics granted restricted stock units covering 4,750 shares
- ➤Awards target one newly hired non-executive employee under Nasdaq Rule 5635(c)(4)
- ➤Options vest 25% after one year, then monthly over 36 substantially equal installments
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.
Get started
Create a free account to read the full story.